CCI finds no abuse of dominance by St. Stephen’s Hospital in Delhi healthcare pricing case.

May 21, 2026 : The Competition Commission of India (CCI) has ruled in favour of Delhi-based St. Stephen’s Hospital in a long-running case examining allegations of excessive pricing and abuse of dominance by private super-specialty hospitals in Delhi NCR. In a significant order dealing with hospital pricing practices, the CCI held that merely charging higher prices for room rent, medical tests, consumables, medicines, or diagnostic services cannot automatically amount to abuse of dominant position under the Competition Act, 2002, unless there is clear evidence of “excessive” and “unfair” pricing.

The case originated from a complaint filed in 2015 by Vivek Sharma under Section 19(1)(a) of the Competition Act against Becton Dickinson India Pvt. Ltd. and Max Super Specialty Hospital, Patparganj, alleging that syringes sold inside the hospital carried artificially inflated Maximum Retail Prices compared to identical products available in the open market. During the investigation, the Director General (DG) expanded the probe to cover multiple super-specialty hospitals in Delhi, including St. Stephen’s Hospital, and examined allegations relating to excessive pricing of room rent, medical tests, medical devices, medicines, and consumables supplied to admitted patients.

The DG had concluded that private hospitals effectively operated as independent “aftermarkets” for admitted patients and were dominant within those ecosystems. It alleged that hospitals earned significant profit margins on consumables and medicines and often encouraged patients to use only in-house pharmacies and diagnostic facilities. The DG also compared hospital pricing with standalone diagnostic laboratories and nearby hotels to argue that charges imposed by hospitals were substantially higher.

However, while examining the case against St. Stephen’s Hospital, the CCI took a different view. The Commission noted that St. Stephen’s Hospital was distinct from many other hospitals investigated because it allowed patients to procure medicines, consumables, medical devices, and tests from outside vendors. The hospital argued that there were multiple pharmacies operating near its premises and that patients were never compelled to purchase products only from its in-house facilities.

The hospital also challenged the DG’s market definition and argued that patients exercise choice before admission by comparing hospitals based on cost, facilities, reputation, accessibility, and treatment packages. According to the hospital, healthcare services cannot be viewed in isolation after admission because patients are aware of estimated treatment costs beforehand and can choose alternative hospitals if dissatisfied.

After analysing the matter in detail, the CCI rejected the DG’s narrow “aftermarket abuse” theory for elective treatments and held that the relevant market should instead be considered as the broader “market for provision of healthcare services by super speciality hospitals in Delhi NCR.” The Commission observed that patients generally receive estimated treatment costs before admission and are capable of comparing overall healthcare expenses across hospitals.

The order contains extensive discussion on the concept of aftermarket abuse under competition law. Referring to international jurisprudence, including the European Court ruling in United Brands v. Commission of the European Communities, the Commission explained that excessive pricing requires proof that prices are both “excessive” in relation to cost and “unfair” when compared with competing products or services.

Importantly, the Commission held that hospitals and hotels cannot be compared for determining excessive room rent because hospital rooms are designed for clinical care and emergency response, unlike ordinary accommodation facilities. The CCI observed that hospital rooms involve specialized infrastructure, medical staff availability, and patient monitoring systems that fundamentally distinguish them from hotel services. It stated that “hospital rooms and three/four-star hotel’s rooms are different relevant product and they are not substitutable.”

On medical tests and diagnostics, the Commission found that the DG’s comparisons with standalone diagnostic laboratories produced “mixed results.” While certain tests at St. Stephen’s Hospital were costlier than those at independent labs, several others were cheaper. The Commission also emphasized that hospital laboratories operate 24×7 and provide faster turnaround times, which increases operational costs compared to standalone diagnostic centres.

The CCI noted that the DG had failed to compare St. Stephen’s pricing with similarly placed hospitals offering comparable services. It observed that a finding of unfair pricing could arise only if prices were “significantly higher in comparison with prices charged by other hospitals providing similar services.” Since no such comprehensive comparison was carried out, the Commission held that excessive pricing allegations were not conclusively established.

The Commission similarly rejected allegations relating to medical devices, X-rays, MRIs, ultrasound tests, and implants. It found that the hospital had not breached price ceilings fixed by the National Pharmaceutical Pricing Authority (NPPA) for regulated medical devices such as stents and that pricing variations alone did not establish abuse of dominance.

In a broader legal and policy context, the order also discussed the current regulatory framework governing healthcare pricing in India. The CCI referred to the Drugs and Cosmetics Act, 1940, the Drug Price Control Order (DPCO), 2013, and the role of the NPPA in regulating prices of essential medicines and certain medical devices. The Commission further cited the Supreme Court’s March 2025 judgment in Siddharth Dalmia v. Union of India, where the apex court observed that regulation of pricing practices in private hospitals involves larger policy considerations best addressed by policymakers rather than courts.

The ruling is likely to have significant implications for India’s private healthcare sector. It clarifies that high pricing by hospitals, by itself, does not automatically violate competition law unless supported by evidence of exploitative conduct and lack of consumer choice. At the same time, the Commission acknowledged that concerns regarding “locked-in” patients and post-admission dependence on hospital services may still require scrutiny in limited situations, especially where switching hospitals becomes practically difficult during ongoing treatment.

The decision also underscores the evidentiary burden required in competition law cases involving healthcare pricing. The Commission effectively held that broad allegations of profiteering are insufficient unless supported by rigorous economic analysis, cost comparisons, and proof that hospitals acted independently of competitive market constraints.

Case Reference : Case No. 77(12) of 2015, Vivek Sharma v. St. Stephen’s Hospital, Delhi, Competition Commission of India.